Browse our anti-IGFBP4 (IGFBP4) Antibodies

Human Insulin-Like Growth Factor Binding Protein 4 (IGFBP4) interaction partners

1. Igfbp4 down-regulation significantly correlated with EZH2 overexpression and poor survivals of HCC patients. IGFBP4 stimulated AKT/EZH2 phosphorylation to abrogate H3K27me3-mediated silencing, forming a reciprocal feedback loop that suppressed core transcription factor networks (FOXA1/HNF1A/HNF4A/KLF9/NR1H4) for normal liver homeostasis.

2. In STEMI patients, Stanniocalcin-2 and IGFBP-4 emerged as independent predictors of all-cause death and readmission due to HF. The Stanniocalcin-2/PAPP-A/IGFBP-4 axis exhibits a significant role in STEMI risk stratification.

3. The authors also identified single-nucleotide polymorphisms in NRP2 and IGFBP4 loci that increase and reduce risk of lichen planus in hepatitis C virus-infected patients, respectively.

4. the results of this study raise the possibility that human mesenchymal stem cells actions involve a negative-regulatory mechanism that suppresses Treg proliferation by releasing IGFBP-4

5. IGFBP-4 maybe act as a potential negative regulator in the progression of lung cancer through downregulation of COX-2.

6. Patients with type 2 Diabetes Mellitus had lower serum concentrations of IGFBP-4 compared to controls.

7. Data show that insulin-like growth factor binding protein-4 (IGFBP-4) was significantly elevated in lupus nephritis, particularly those with renal pathology chronicity changes.

8. The present study provides the first evidence that apoptosis inhibitor of macrophages binds to IGFBP2, 3 and 4.

9. Data show that co-transfection with cDNA encoding stanniocalcin-1 abrogates the proteolytic activity of pregnancy-associated plasma protein-A (PAPP-A) toward IGF-binding protein 4 (IGFBP-4).

10. PLasma IGFBP-4 levels are not acutely altered following myocardial infarction treated with heparin and percutaneous coronary intervention.

11. High IGFBP-4 fragment levels were associated with increased all-cause and cardiovascular mortality rates in T1D patients with and without diabetic nephropathy.

12. Data indicate co-localization of insulin-like growth factor binding proteins IGFBP-4, IGFBP-5 in the syncytiotrophoblast layer of first trimester placental villi as early as 5 weeks of gestational age.

13. IGF-1/IGFbp4 signaling regulated the post-developmental adipose tissue expansion.

14. Despite the relation of CT-IGFBP4 to a more severe coronary artery disease, CT- and NT-IGFBP4, in contrast to our report based on total PAPP-A, failed to predict any long-term outcomes in patients with stable cardiovascular disease.

15. these findings demonstrate an oncogenic property for IBP in promoting the metastatic potential of breast cancer cells.

16. PAPP-A and IGFBP-4 gene expression (microarray analysis) was significantly upregulated in IL-1beta- or TNF-alpha-exposed cells.

17. IGFBP-4 modulates the efficiency of estrogen-triggered activation of the Akt/PKB signaling pathway which has been associated with growth factor/ ERalpha cross-talks.

18. Epigenetic silencing of UCHL1 and IGFBP4 in giant cell tumors may be important for malignant transformation of the cells

19. IGFBP-4 was by far the most predominant IGFBP by immunoassay

20. role of IGFBP-4 in regulating IGF bioavailability and provide new clues for the prevention and treatment of FGR (Fetal growth restriction).

Mouse (Murine) Insulin-Like Growth Factor Binding Protein 4 (IGFBP4) interaction partners

1. Igfbp4 is required for inguinal fat expansion in female mice but not in male mice. However, gonadal WAT expansion, which is prevented by estrogen during high-fat diet, does not require Igfbp4.

2. IGFBP-4 modulates the skeleton in a gender-specific manner, acting as both a cell autonomous and cell non-autonomous factor.

3. exerts a negative effect on basal intestinal growth but plays a positive regulatory role in the intestinotropic actions of GLP-2

4. IGF-1/IGFbp4 signaling regulated the post-developmental adipose tissue expansion.

5. Igfbp2-5 are expressed in distinct and complementary patterns during cochlear development.

6. SOX9 is a transcriptional regulator of IGFBP-4 and that SOX9-induced activation of IGFBP-4 may be one of the mechanisms by which SOX9 suppresses cell proliferation and progression of colon cancer.

7. findings indicate that the defect in p53 function and the increased proteolysis of IGFBP-4, we had observed, represent two components of the same pathway, which contributes to the oncogenic function of Skp2B

8. Inactivation of IGFBP4 diminished the anabolic effects of PAPP-A on bone.

9. Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice

10. IGFBP-4 is a potential growth inhibitor of lymphoid tissues.

11. This study demonstrates that ES of muscle cells in vitro not only directly modulates the gene expression of contractile proteins but also modulates proteins that are part of the IGF regulatory system, in particular IGFBP-4.

12. Crystallization, heparin and IGF binding, and osteogenic activity of IGFBP4 in its native conformation

13. Overexpression of Hbegf in transgenic mice downregulates Igfbp4.

14. provide direct evidence for combinatorial effects of IGFBP-3, -4, and -5 in both metabolism and at least some soft tissues

15. IGFBP-4 may have a role in increasing necrosis and apoptosis, but in decreasing mitosis

16. Results indicate that IGFBP-4 functions as a local reservoir to optimize IGF-II actions needed for normal embryogenesis, and also establish that IGFBP-4 proteolysis is required to activate most, if not all, IGF-II mediated growth-promoting activity.

17. IGFBP-4 is an inhibitor of the canonical Wnt signalling required for cardiogenesis and provides a molecular link between insulin-like growth factor signalling and Wnt signalling

18. Data suggest that loss of expression of IGFBPs (IGFBP-3 and IGFBP-4) in tumor cells treated with EGFR tyrosine kinase inhibitors derepresses IGFIR signaling, which in turn mediates resistance to EGFR antagonists.

19. SOD1(G93A) mutant transgenic mice as a model of amyotrophic lateral sclerosis (ALS) and immunohistochemical studies to investigate the changes of insulin-like growth factor-binding protein 4 (IGFBP4) in the central nervous system.

Cow (Bovine) Insulin-Like Growth Factor Binding Protein 4 (IGFBP4) interaction partners

1. IGFBP4 maternal blood concentrations were lower during pregnancy than during non-pregnant cycles and synchronized control cycles. The lower IGFBP4 in maternal blood may result in an increase of free insulin-like growth factor- for local action.

2. follicular dominance was associated with low or decreased follicular fluid concentrations of IGFBP-4 and -5

Pig (Porcine) Insulin-Like Growth Factor Binding Protein 4 (IGFBP4) interaction partners

1. Sequence analysis showed that the porcine IBP4 gene encodes a protein of 259 amino acids which shares high homology with the insulin-like growth factor binding protein 4 (IBP4) of eight species.